What type of study is this?

This is a Pre-Registered Trial study.

December 8, 2025BloodOpen Access

Epcoritamab monotherapy demonstrates promising efficacy in patients with Richter transformation (RT): 2-year follow-up results from arm 2A of the phase 1b/2 EPCORE CLL-1 trial

View Full Paper

Ask AI

Bookmark

Authors

Monotherapy with epcoritamab demonstrates 57% complete response in Richter transformation patients, suggesting a potential new standard of care.

Overall response rate for epcoritamab monotherapy reached 48%, highlighting its promising efficacy in Richter transformation cases.
In patients treated as first-line therapy, 57% achieved complete response, indicating strong initial clinical benefits from epcoritamab.
Cytokine release syndrome was noted in 86% of patients, with most cases being low-grade and resolving swiftly within three days.
These findings support further exploration of epcoritamab as a core therapy in managing Richter transformation in chronic lymphocytic leukemia.

Kater et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Monotherapy with epcoritamab demonstrates 57% complete response in Richter transformation patients, suggesting a potential new standard of care.

Overall response rate for epcoritamab monotherapy reached 48%, highlighting its promising efficacy in Richter transformation cases.
In patients treated as first-line therapy, 57% achieved complete response, indicating strong initial clinical benefits from epcoritamab.
Cytokine release syndrome was noted in 86% of patients, with most cases being low-grade and resolving swiftly within three days.
These findings support further exploration of epcoritamab as a core therapy in managing Richter transformation in chronic lymphocytic leukemia.

Kater et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark